Neurocrine presents new data on patient-reported improvements with INGREZZA

Neurocrine (NBIX) Biosciences announced the presentation of new analyses from a Phase 4 randomized withdrawal study demonstrating significant patient-reported improvements in health-related quality of life and functional measures among adults aged 65 years and older with tardive dyskinesia who received continued treatment with INGREZZA capsules. Findings will be presented at the 2025 American Association of Nurse Practitioners National Conference in San Diego. These post-hoc analyses of older adults expand on recently announced Phase 4 study results, which demonstrated that continued treatment with INGREZZA improved functional status and quality of life measures across the general patient population. Patients who received continued treatment with INGREZZA reported significant improvements in health-related quality of life and functional status, compared with those randomized to placebo. Two clinically validated scales were used to assess patient-reported outcomes, providing a comprehensive and scientifically robust measure of health status: The EuroQol 5-Dimension 5-Level assessment tool, which measures health-related quality of life across five dimensions of health status; The Sheehan Disability Scale, which measures patient-reported functional impairment in work/school, social life and family/home life impairment.